Sanofi-Aventis v. Sun Pharmaceutical Industries Ltd.
1:08-cv-00350
Overview
Parties
Defendant
Sun Pharma Global Inc. Operating Company
Represented By
1 Attorneys ListedPotter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Sun Pharma Advanced Research Company Ltd. Operating Company
Represented By
3 Attorneys ListedPotter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Sun Pharmaceutical Industries Inc. Operating Company
Represented By
1 Attorneys ListedPotter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Sun Pharmaceutical Industries Ltd. Operating Company
Represented By
1 Attorneys ListedPotter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Plaintiff
Sanofi-Aventis US LLC Operating Company
Represented By
1 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Sanofi-Aventis Operating Company
Represented By
1 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 3 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 4,661,491 Asserted | Asserted Patent | View Official Patent → |
| π«π· France | FR 8507950 | France Counterpart | View Official Patent → |
| π«π· France | FR 2582513 B1 | France Counterpart | View Official Patent → |
Sanofi-Aventis v. Actavis South Atlantic LLC
Sanofi-Aventis v. Barr Laboratories Inc.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US4661491
Alfuzosine compositions and use
|
Filed: 1986-05-27
Issued: 1987-04-28
|
Expired (Term Ended)
+365d PTA
Expires: 2007-05-27
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
High PTA (+365 days) / Cellect Scrutiny β Over 365 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).